These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 10534335

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
    Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK.
    Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Epidemiology of liver disease in cystic fibrosis: a longitudinal study.
    Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F.
    J Hepatol; 2004 Dec; 41(6):920-5. PubMed ID: 15582124
    [Abstract] [Full Text] [Related]

  • 6. Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome.
    Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, Giunta A.
    Hepatology; 2002 Dec; 36(6):1374-82. PubMed ID: 12447862
    [Abstract] [Full Text] [Related]

  • 7. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
    Lindblad A, Glaumann H, Strandvik B.
    Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
    [Abstract] [Full Text] [Related]

  • 8. Liver disease in children with cystic fibrosis.
    Diwakar V, Pearson L, Beath S.
    Paediatr Respir Rev; 2001 Dec; 2(4):340-9. PubMed ID: 12052306
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.
    Harrison SA, Torgerson S, Hayashi PH.
    Am J Gastroenterol; 2003 Sep; 98(9):2042-7. PubMed ID: 14499785
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cystic fibrosis-associated liver disease: a population-based study.
    Corbett K, Kelleher S, Rowland M, Daly L, Drumm B, Canny G, Greally P, Hayes R, Bourke B.
    J Pediatr; 2004 Sep; 145(3):327-32. PubMed ID: 15343185
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. All liver recipients benefit from the protocol 10-year liver biopsies.
    Sebagh M, Rifai K, Féray C, Yilmaz F, Falissard B, Roche B, Bismuth H, Samuel D, Reynès M.
    Hepatology; 2003 Jun; 37(6):1293-301. PubMed ID: 12774007
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Aspartate aminotransferase (AST) more than alanine aminotransferase (ALT) levels predict the progression of liver fibrosis in chronic HCV infection].
    Stránský J, Ryzlová M, Striteský J, Horák J.
    Vnitr Lek; 2002 Oct; 48(10):924-8. PubMed ID: 16737138
    [Abstract] [Full Text] [Related]

  • 19. Partial splenectomy for portal hypertension in cystic fibrosis related liver disease.
    Louis D, Duc ML, Reix P, Chazalette JP, Durieu I, Feigelson J, Bellon G.
    Pediatr Pulmonol; 2007 Dec; 42(12):1173-80. PubMed ID: 17968998
    [Abstract] [Full Text] [Related]

  • 20. Liver disease in cystic fibrosis.
    Colombo C, Russo MC, Zazzeron L, Romano G.
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S49-55. PubMed ID: 16819402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.